Septerna to Present at TD Cowen 45th Annual Health Care Conference
Septerna (Nasdaq: SEPN), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, has announced its participation in an upcoming investor event. The company's CEO and Co-founder, Jeffrey Finer, M.D., Ph.D., will deliver a presentation at the TD Cowen 45th Annual Health Care Conference in Boston.
The presentation is scheduled for Wednesday, March 5, 2025, at 10:30 a.m. ET. This conference appearance represents an opportunity for Septerna to showcase its innovative GPCR drug discovery platform to the investment community.
Septerna (Nasdaq: SEPN), un'azienda biotecnologica focalizzata sulla scoperta di farmaci tramite recettori accoppiati a proteine G (GPCR), ha annunciato la sua partecipazione a un prossimo evento per investitori. Il CEO e co-fondatore dell'azienda, Jeffrey Finer, M.D., Ph.D., presenterà durante il 45° Congresso Annuale sulla Salute di TD Cowen a Boston.
La presentazione è programmata per mercoledì 5 marzo 2025, alle 10:30 ET. Questa apparizione alla conferenza rappresenta un'opportunità per Septerna di mostrare alla comunità degli investitori la sua innovativa piattaforma di scoperta di farmaci GPCR.
Septerna (Nasdaq: SEPN), una empresa biotecnológica centrada en el descubrimiento de fármacos mediante receptores acoplados a proteínas G (GPCR), ha anunciado su participación en un próximo evento para inversores. El CEO y cofundador de la empresa, Jeffrey Finer, M.D., Ph.D., realizará una presentación en la 45ª Conferencia Anual de Salud de TD Cowen en Boston.
La presentación está programada para miércoles 5 de marzo de 2025, a las 10:30 a.m. ET. Esta aparición en la conferencia representa una oportunidad para que Septerna muestre su innovadora plataforma de descubrimiento de fármacos GPCR a la comunidad inversora.
Septerna (Nasdaq: SEPN), G 단백질 결합 수용체(GPCR) 약물 발견에 중점을 둔 생명공학 회사가 다가오는 투자자 행사에 참여한다고 발표했습니다. 회사의 CEO이자 공동 창립자인 Jeffrey Finer, M.D., Ph.D.가 보스턴에서 열리는 TD Cowen 제45회 연례 건강 관리 컨퍼런스에서 발표를 할 예정입니다.
발표는 2025년 3월 5일 수요일 오전 10시 30분 ET로 예정되어 있습니다. 이번 컨퍼런스는 Septerna가 투자 커뮤니티에 혁신적인 GPCR 약물 발견 플랫폼을 선보일 수 있는 기회를 제공합니다.
Septerna (Nasdaq: SEPN), une entreprise biotechnologique axée sur la découverte de médicaments via des récepteurs couplés aux protéines G (GPCR), a annoncé sa participation à un prochain événement pour investisseurs. Le PDG et co-fondateur de l'entreprise, Jeffrey Finer, M.D., Ph.D., fera une présentation lors de la 45e Conférence Annuelle de Santé de TD Cowen à Boston.
La présentation est prévue pour mercredi 5 mars 2025, à 10h30 ET. Cette apparition à la conférence représente une opportunité pour Septerna de présenter sa plateforme innovante de découverte de médicaments GPCR à la communauté des investisseurs.
Septerna (Nasdaq: SEPN), ein biotechnologisches Unternehmen, das sich auf die Arzneimittelentdeckung über G-Protein-gekoppelte Rezeptoren (GPCR) konzentriert, hat seine Teilnahme an einer bevorstehenden Investorenveranstaltung bekannt gegeben. Der CEO und Mitbegründer des Unternehmens, Jeffrey Finer, M.D., Ph.D., wird auf der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston eine Präsentation halten.
Die Präsentation ist für Mittwoch, den 5. März 2025, um 10:30 Uhr ET geplant. Dieses Konferenzauftritt bietet Septerna die Möglichkeit, der Investmentgemeinschaft seine innovative GPCR-Arzneimittelentdeckungsplattform vorzustellen.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston.
About Septerna
Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Septerna (SEPN) presenting at the TD Cowen Healthcare Conference 2025?
Who will represent Septerna (SEPN) at the TD Cowen Healthcare Conference?
What is Septerna's (SEPN) main focus in drug discovery?
Which major healthcare conference is Septerna (SEPN) participating in March 2025?
